FGFR3 and achondroplasia: One of the first studies to use CNP as a potential treatment for skeletal dysplasia was done in a mouse model of achondroplasia, the most common form of dwarfism caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene.